Page last updated: 2024-09-04

2-methoxystypandrone and Bone Loss, Osteoclastic

2-methoxystypandrone has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, CC; Chiou, WF; Huang, CY; Liao, JF	1

Other Studies

1 other study(ies) available for 2-methoxystypandrone and Bone Loss, Osteoclastic

Article	Year
2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes. British journal of pharmacology, 2010, Volume: 161, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Down-Regulation; Drugs, Chinese Herbal; Fallopia japonica; Macrophages; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinases; Naphthoquinones; Osteoclasts; Protease Inhibitors; Protein Binding; RANK Ligand; Signal Transduction; TNF Receptor-Associated Factor 6	2010

Article

Year

2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.

British journal of pharmacology, 2010, Volume: 161, Issue:2

Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Down-Regulation; Drugs, Chinese Herbal; Fallopia japonica; Macrophages; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinases; Naphthoquinones; Osteoclasts; Protease Inhibitors; Protein Binding; RANK Ligand; Signal Transduction; TNF Receptor-Associated Factor 6

2010